

**CORONA Remedies Limited**

(Formerly known as CORONA Remedies Private Limited)

Regd. Office: CORONA House

C- Mondeal Business Park, Near Gurudwara, S.G. Highway,
Thaltej, Ahmedabad 380 059, Gujarat, India.

Tele.: +079 - 40233000

Online at : Info@coronaremedies.com

website : www.coronaremedies.com

CIN : L24231GJ2004PLC044656

February 02, 2026

To,
Listing Operation Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai-400001
(Scrip Code: 544644)

To,
Listing Compliance Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G, Bandra Kurla
Complex, Bandra (East), Mumbai-400051
(SYMBOL: CORONA)

Dear Sir / Madam,

Sub.: Outcome of the Board Meeting

Ref.: Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations), we would like to inform that the Board at its meeting held today has, inter alia, approved the unaudited standalone and consolidated financial results along with limited review reports of the Company for the third quarter and nine months ended December 31, 2025. The said financial results are enclosed herewith.

In terms of Regulation 47 of the Listing Regulations, the Company will publish an advertisement for unaudited standalone and consolidated financial results for the third quarter and nine months ended December 31, 2025.

The above results along with limited review reports are also being made available on the website of the Company at www.coronaremedies.com

A Press Release on financial results which is being submitted to the media, is also enclosed herewith.

The Board meeting commenced at 04:00 p.m. and concluded at 05:15 p.m.

You are requested to take note of the above.

Thanking you.

Yours faithfully,

For **CORONA Remedies Limited**

Chetna Dharajiya
Company Secretary and Compliance Officer

Encl.: A/a

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF CORONA REMEDIES LIMITED (FORMERLY KNOWN AS CORONA REMEDIES PRIVATE LIMITED)

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of **CORONA Remedies Limited (formerly known as CORONA Remedies Private Limited)** ("the Company"), for the quarter and nine months ended December 31, 2025 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.



**Deloitte
Haskins & Sells LLP**

5. As stated in Note 4 to the Statement, financial information relating to the quarter ended December 31, 2024 included in Statement has been furnished to us by the Management and has not been subject to review by us.

Our conclusion on the statement is not modified in respect of this matter.

For DELOITTE HASKINS & SELLS LLP
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)



H. S. Sutaria

Hardik Sutaria
Partner
Membership No. 116642
(UDIN: 26116642KSRBVK3167)

Place: Ahmedabad
Date: February 02, 2026



CORONA Remedies Limited
(formerly known as CORONA Remedies Private Limited)
Regd. Office: CORONA House,
C - Mondeal Business Park, Near Gurudwara, S.G.Highway,
Thaltej, Ahmedabad-380059, Gujarat, India
Tele.: +079-40233000 | Website : www.coronaremedies.com
CIN : L24231GJ2004PLC044656

Statement of Unaudited Standalone Financial Results for the Quarter and Nine Months ended 31 December 2025

(Amount Rs. in Crores except per share data)

Sr. No.	Particulars	For Quarter Ended			For Nine Months Ended		For Year Ended
		31 Dec 2025 (Unaudited)	30 Sep 2025 (Unaudited)	31 Dec 2024 (Unaudited) (Refer note 4)	31 Dec 2025 (Unaudited)	31 Dec 2024 (Audited) (Refer note 5)	31 March 2025 (Audited)
1	Income :						
a	Revenue from operations	342.42	361.13	297.69	1,050.09	902.73	1,196.42
b	Other income	2.24	2.27	0.76	6.54	4.51	5.93
	Total income	344.66	363.40	298.45	1,056.63	907.24	1,202.35
2	Expenses :						
a	Cost of materials consumed	24.82	25.90	24.71	75.78	76.40	102.29
b	Purchases of Stock-in-trade	41.15	28.11	35.17	104.04	112.19	157.97
c	Changes in inventories of finished goods, stock-in-trade and work-in-progress	(5.70)	14.64	(4.68)	14.88	(8.93)	(23.74)
d	Employee benefits expense	95.94	103.00	89.47	296.39	261.29	346.14
e	Finance costs	1.66	1.93	2.39	5.59	8.40	10.60
f	Depreciation and amortization expenses	9.45	9.20	9.69	27.58	27.12	37.16
g	Other expenses	103.05	111.01	83.60	327.58	276.02	373.78
	Total expenses	270.37	293.79	240.35	851.84	752.49	1,004.20
3	Profit before exceptional item and tax (1-2)	74.29	69.61	58.10	204.79	154.75	198.15
4	Exceptional item :						
a	Statutory impact of new Labour Codes (Refer note 6)	19.10	-	-	19.10	-	-
5	Profit before tax (3-4)	55.19	69.61	58.10	185.69	154.75	198.15
6	Tax expense :						
a	Current tax expense	17.10	15.85	14.09	48.14	36.31	45.55
b	(Excess) provision for tax relating to earlier periods / year	-	-	-	(0.89)	(0.75)	(0.75)
c	Deferred tax expense / (income)	(3.16)	1.61	(0.76)	(1.36)	1.48	4.30
	Total Tax expense	13.94	17.46	13.33	45.89	37.04	49.10
7	Net Profit after tax for the period / year (5-6)	41.25	52.15	44.77	139.80	117.71	149.05
8	Other comprehensive income / (loss) for the period/year						
a	Items that will not be reclassified to profit and loss	(0.08)	0.41	(0.23)	(0.75)	(0.81)	(1.16)
b	Income tax effect on above item	0.02	(0.10)	0.05	0.19	0.20	0.29
	Total Other comprehensive income / (loss) for the period/year	(0.06)	0.31	(0.18)	(0.56)	(0.61)	(0.87)
9	Total comprehensive income for the period/year (7+8)	41.19	52.46	44.59	139.24	117.10	148.18
10	Paid-up equity share capital (face value Rs.10/-)	61.16	61.16	61.16	61.16	61.16	61.16
11	Other Equity						544.56
12	Earnings per share (not annualised for the quarter and nine months)						
a	Basic (Rs.)	6.74	8.53	7.32	22.86	19.25	24.37
b	Diluted (Rs.)	6.74	8.53	7.32	22.86	19.25	24.37



Notes to unaudited standalone financial results for the Quarter and Nine Months ended 31 December 2025 :

- 1 The Company's equity shares have been listed on the National Stock Exchange of India ("NSE") and on BSE Limited ("BSE") on 15 December, 2025, by completing Initial Public Offering through offer for sale of 61,74,051 equity shares of face value of Rs.10 each at an issue price of Rs.1,008 per equity share (for employees) and Rs.1,062 per equity share (other than employees) by selling shareholders. The total initial public offer expenses (except listing fees) are entirely allocated to the selling shareholders.
- 2 The above unaudited standalone financial results of the Company has been reviewed by the Audit Committee and subsequently approved by Board of Directors at their meeting held on 02 February 2026. The Statutory Auditors have carried out limited review of the aforesaid results.
- 3 These unaudited standalone financial results have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 ["Ind AS"] as prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulation 33 of Securities and Exchange Board of India [Listing Obligations and Disclosure Requirements] Regulations, 2015, as amended.
- 4 The standalone financial results for the quarter ended 31 December 2024 has not been subject to limited review. However the management has exercised necessary diligence to ensure that the financial results of that period provide a true and fair view of the Company's affairs.
- 5 The standalone financial results for the nine months period ended 31 December 2024 have been extracted from the audited special purpose interim financial statements which were prepared for IPO filings.
- 6 **One time impact of New Labour Codes :**
On 21 November 2025, the Government of India notified the four Labour Codes - the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 - consolidating 29 existing labour laws. The Ministry of Labour & Employment published draft Central Rules and FAQs to enable assessment of the financial impact due to changes in regulations. The Company has assessed and disclosed the incremental impact of these changes on the basis of the guidance provided by the Institute of Chartered Accountants of India. Considering the materiality and regulatory-driven, non-recurring nature of this impact, the Company has presented such incremental impact as "Statutory impact of new Labour Codes" under "Exceptional Items" amounting Rs.19.10 crores (Post tax Rs.14.29 crores) in the financial results for the period ended 31 December 2025.
The incremental impact consisting of gratuity of Rs.13.59 crores and long-term compensated absences of Rs.5.51 crores primarily arises due to change in wage definition. The Company continues to monitor the finalisation of Central / State Rules and clarifications from the Government on other aspects of the Labour Code and would provide appropriate accounting effect on the basis of such developments as needed.
- 7 The Company has only one reportable business segment i.e. 'Pharmaceuticals'.

For CORONA Remedies Limited,



Nirav K. Mehta
Managing Director & CEO
DIN : 01644041



Place: Ahmedabad
Date : 02 February 2026

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF CORONA REMEDIES LIMITED (FORMERLY KNOWN AS CORONA REMEDIES PRIVATE LIMITED)

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **CORONA Remedies Limited (formerly known as CORONA Remedies Private Limited)** ("the Parent") and its share of the net profit/(loss) after tax and total comprehensive income/(loss) of its associate for the quarter and nine months ended December 31, 2025 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. The Statement includes the results of the following entities:
 - a) CORONA Remedies Limited (formerly known as CORONA Remedies Private Limited) - Parent
 - b) La Chandra Pharma Labs Private Limited - Associate
5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains material misstatement.



6. The Unaudited consolidated financial results includes the Parent's share of profit/(loss) after tax of Rs.0.02 Crores and Rs.(0.01) Crores for the quarter and nine months ended December 31, 2025 respectively and total comprehensive income/(loss) of Rs. 0.02 Crores and Rs. (0.01) Crores for the quarter and nine months ended December 31, 2025 respectively, as considered in the Statement, in respect of one associate, based on its interim financial information which have not been reviewed by its auditor. According to the information and explanations given to us by the Management, this interim financial information is not material to the unaudited consolidated financial results.

Our Conclusion on the Statement is not modified in respect of our reliance on the financial information certified by the Management.

7. As stated in Note 4 to the Statement, financial information relating to the quarter ended December 31, 2024, included in Statement has been furnished to us by the Management and has not been subject to review by us.

Our conclusion on the statement is not modified in respect of this matter.

For **DELOITTE HASKINS & SELLS LLP**

Chartered Accountants

(Firm's Registration No. 117366W/W-100018)



H. S. Sutar

Hardik Sutar

Partner

Membership No. 116642

(UDIN: 26116642PKFWRW5158)

Place: Ahmedabad

Date: February 02, 2026



CORONA Remedies Limited
(formerly known as CORONA Remedies Private Limited)
Regd. Office: CORONA House,
C - Mondeal Business Park, Near Gurudwara, S.G.Highway,
Thaltej, Ahmedabad-380059, Gujarat, India
Tele.: +079-40233000 | Website : www.coronaremedies.com
CIN : L24231GJ2004PLC044656

Statement of Unaudited Consolidated Financial Results for the Quarter and Nine Months ended 31 December 2025

(Amount Rs. in Crores except per share data)

Sr. No.	Particulars	For Quarter Ended			For Nine Months Ended		For Year Ended
		31 Dec 2025 (Unaudited)	30 Sep 2025 (Unaudited)	31 Dec 2024 (Unaudited) (Refer note 4)	31 Dec 2025 (Unaudited)	31 Dec 2024 (Audited) (Refer note 5)	31 March 2025 (Audited)
1	Income :						
a	Revenue from operations	342.42	361.13	297.69	1,050.09	902.73	1,196.42
b	Other income	2.24	2.27	0.76	6.54	4.51	5.93
	Total income	344.66	363.40	298.45	1,056.63	907.24	1,202.35
2	Expenses :						
a	Cost of materials consumed	24.82	25.90	24.71	75.78	76.40	102.29
b	Purchases of Stock-in-trade	41.15	28.11	35.17	104.04	112.19	157.97
c	Changes in inventories of finished goods, stock-in-trade and work-in-progress	(5.70)	14.64	(4.68)	14.88	(8.93)	(23.74)
d	Employee benefits expense	95.94	103.00	89.47	296.39	261.29	346.14
e	Finance costs	1.66	1.93	2.39	5.59	8.40	10.60
f	Depreciation and amortization expenses	9.45	9.20	9.69	27.58	27.12	37.16
g	Other expenses	103.05	111.01	83.60	327.58	276.02	373.78
	Total expenses	270.37	293.79	240.35	851.84	752.49	1,004.20
3	Profit before share of profit / (loss) of associate, exceptional item and Tax (1-2)	74.29	69.61	58.10	204.79	154.75	198.15
4	Exceptional item :						
a	Statutory impact of new Labour Codes (Refer note 6)	19.10	-	-	19.10	-	-
5	Share of profit / (loss) of associate (net of tax)	0.02	0.17	0.18	(0.01)	0.17	0.38
6	Profit before tax (3-4+5)	55.21	69.78	58.28	185.68	154.92	198.53
7	Tax expense :						
a	Current tax expense	17.10	15.85	14.09	48.14	36.31	45.55
b	(Excess) provision for tax relating to earlier periods / year	-	-	-	(0.89)	(0.75)	(0.75)
c	Deferred tax expense / (income)	(3.16)	1.61	(0.76)	(1.36)	1.48	4.30
	Tax expense	13.94	17.46	13.33	45.89	37.04	49.10
8	Net Profit after tax for the period / year (6-7)	41.27	52.32	44.95	139.79	117.88	149.43
9	Other comprehensive income / (loss) for the period/year						
a	Items that will not be reclassified to profit and loss	(0.08)	0.41	(0.23)	(0.75)	(0.81)	(1.16)
b	Income tax effect on above item	0.02	(0.10)	0.05	0.19	0.20	0.29
	Total Other comprehensive income / (loss) for the period/year	(0.06)	0.31	(0.18)	(0.56)	(0.61)	(0.87)
10	Total comprehensive income for the period/year (8+9)	41.21	52.63	44.77	139.23	117.27	148.56
11	Profit for the year/period attributable to:						
	Owners of the Company	41.27	52.32	44.95	139.79	117.88	149.43
		41.27	52.32	44.95	139.79	117.88	149.43
12	Total Other Comprehensive (loss) for the period/year attributable to:						
	Owners of the Company	(0.06)	0.31	(0.18)	(0.56)	(0.61)	(0.87)
		(0.06)	0.31	(0.18)	(0.56)	(0.61)	(0.87)
13	Total Comprehensive Income for the period/year attributable to:						
	Owners of the Company	41.21	52.63	44.77	139.23	117.27	148.56
		41.21	52.63	44.77	139.23	117.27	148.56
14	Paid-up equity share capital (face value Rs.10/-)	61.16	61.16	61.16	61.16	61.16	61.16
15	Other Equity						545.18
16	Earnings per share (not annualised for the quarter and nine months)						
a	Basic (Rs.)	6.75	8.55	7.35	22.86	19.27	24.43
b	Diluted (Rs.)	6.75	8.55	7.35	22.86	19.27	24.43



Notes to unaudited consolidated financial results for the Quarter and Nine Months ended 31 December 2025 :

- 1 The Company's equity shares have been listed on the National Stock Exchange of India ("NSE") and on BSE Limited ("BSE") on 15 December, 2025, by completing Initial Public Offering through offer for sale of 61,74,051 equity shares of face value of Rs.10 each at an issue price of Rs.1,008 per equity share (for employees) and Rs.1,062 per equity share (other than employees) by selling shareholders. The total initial public offer expenses (except listing fees) are entirely allocated to the selling shareholders.
- 2 The above unaudited consolidated financial results of the Company and its associate have been reviewed by the Audit Committee and subsequently approved by Board of Directors at their meeting held on 02 February 2026. The Statutory Auditors have carried out limited review of the aforesaid results.
- 3 These unaudited consolidated financial results have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 ["Ind AS"] as prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulation 33 of Securities and Exchange Board of India [Listing Obligations and Disclosure Requirements] Regulations, 2015, as amended.
- 4 The consolidated financial results for the quarter ended 31 December 2024 has not been subject to limited review. However the management has exercised necessary diligence to ensure that the financial results of that period provide a true and fair view of the Company's affairs.
- 5 The consolidated financial results for the nine months period ended 31 December 2024 have been extracted from the audited special purpose interim financial statements which were prepared for IPO filings.
- 6 **One time impact of New Labour Codes :**
On 21 November 2025, the Government of India notified the four Labour Codes - the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 - consolidating 29 existing labour laws. The Ministry of Labour & Employment published draft Central Rules and FAQs to enable assessment of the financial impact due to changes in regulations. The Company has assessed and disclosed the incremental impact of these changes on the basis of the guidance provided by the Institute of Chartered Accountants of India. Considering the materiality and regulatory-driven, non-recurring nature of this impact, the Company has presented such incremental impact as "Statutory impact of new Labour Codes" under "Exceptional Items" amounting Rs.19.10 crores (Post tax Rs.14.29 crores) in the financial results for the period ended 31 December 2025.
The incremental impact consisting of gratuity of Rs.13.59 crores and long-term compensated absences of Rs.5.51 crores primarily arises due to change in wage definition. The Company continues to monitor the finalisation of Central / State Rules and clarifications from the Government on other aspects of the Labour Code and would provide appropriate accounting effect on the basis of such developments as needed.
- 7 The Company and its associate has only one reportable business segment i.e. 'Pharmaceuticals'.

For CORONA Remedies Limited,



Nirav K. Mehta
Managing Director & CEO
DIN : 01644041



Place: Ahmedabad
Date : 02 February 2026

Press Release: CORONA Remedies Limited Q3 and Nine Months Dec'25 Results

The Consolidated Revenue from Operations for the quarter and nine months for FY26 stood at ₹ 342.42 Cr. and ₹ 1050.09 Cr. respectively. The Revenue of the above periods grew by 15.0% and 16.3% respectively, on Y-o-Y basis.

PAT ^[1] for the quarter and nine months FY26 was ₹ 55.56 Cr. and ₹ 154.08 Cr. respectively.

The PAT ^[1] of the above periods grew by 23.7% and 30.7% respectively, on Y-o-Y basis.

Ahmedabad, February 02, 2026: CORONA Remedies Limited, today announced the unaudited results for the third quarter and nine months ended December 31, 2025, as approved by its Board of Directors.

Q3 FY26 Financial Highlights:

Particulars (₹ in Cr.)	Q3 FY26	Nine Months FY26
Revenue from Operations	342.42	1,050.09
EBITDA	83.16	231.42
EBITDA Margin	24.3%	22.0%
Profit After Tax ^[1]	55.56	154.08
Profit After Tax Margin ^[1]	16.2%	14.7%

Nine Months FY26 Key Financial Metrics:

Particulars	Nine Months FY26
RoE ^{[1] [2]}	31.1%
RoCE ^{[1] [2]}	48.0%
OCF to EBITDA	86.3%
Net Working Capital Days	18 Days

^[1] Excludes onetime statutory impact of New Labour Code ₹ 19.10 Cr. (Post Tax ₹14.29 Cr.)

^[2] Annualised

Commenting on the results, Mr. Nirav K. Mehta, Managing Director and CEO, CORONA Remedies Limited, said:

“We are delighted to report a strong financial performance in Q3 and 9MFY26. Revenues for Q3 and 9MFY26 grew by 15.0% and 16.3% respectively on a Y-o-Y basis, outperforming the IPM growth. Adjusted Profit after tax for Q3 and 9MFY26 grew by 23.7% and 30.7% respectively on a Y-o-Y basis while maintaining healthy return ratios. We have been consistently delivering on our guided

We have transformed our aspiration of growing Revenues by 15% and PAT by 20% into successful achievement. Our revenues & PAT has grown as per our aspiration in the last 3 quarters and are optimistic of maintaining similar trajectory going forward.

Our strong performance reflects the consistency of our strategy, disciplined execution and deep focus on our core therapeutic segments. By strengthening our field force, expanding our brand portfolio and maintaining a sharp focus on specialists’ prescriptions, we have continued to outperform the market while building a sustainable platform for long-term growth.

I would also like to thank the entire team at CORONA and our stakeholders for their continued support and faith in our business.”

Earnings Call:

CORONA Remedies Limited will conduct earnings call at 04:00 PM (IST) on February 03, 2026 to discuss the financial and business performance of the quarter. To participate in this conference call, please dial the numbers provided below ten minutes ahead of the scheduled start time.

Date & Time	Tuesday, February 03, 2026, 4:00pm IST (HK/Singapore – 6:30 pm, UK – 10:30 am, USA – 5:30 am ET)
Universal Dial In	+91-22-6280 1259 / +91-22-7115 8160
International Dial In	USA: 1 866 746 2133 UK: 0 808 101 1573 Singapore: 800 101 2045 Hong Kong: 800 964 448
Diamond Pass Link	https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber=1267675&linkSecurityString=a117abdc0

About CORONA Remedies Limited:

CORONA Remedies Limited (CORONA), founded in 2004, is an India focused branded pharmaceutical formulation company engaged in developing, manufacturing and marketing products in women's healthcare, cardio-diabeto, pain management, urology and other therapeutic areas.

CORONA manufactures products for healthcare solutions as per international quality standards in its WHO-GMP/ EU GMP-certified plant. CORONA has 2 DSIR-approved R&D centres with 100+ team members including scientists working on new formulation development.

To know more about us, visit www.coronaremedies.com

For further information, please contact: Mr. Sagar Shroff, Strategic Growth Advisors Private Limited (SGA), Mobile: 98205 19303 and Email Id: sagar.shroff@sgapl.net

Disclaimer: Certain statements contained in this document may be statements of future expectations and other forward-looking statements that are based on management's current view and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. None of CORONA Remedies Limited or any of its affiliates, advisors or representatives shall have any liability whatsoever (in negligence or otherwise) for any loss howsoever arising from any use of this document or its content or otherwise arising in connection with this document. This document does not constitute an offer or invitation to purchase or subscribe for any shares and neither it nor any part of it shall form the basis of or be relied upon in connection with any contract or commitment whatsoever.
